Relay Therapeutics (RLAY) Accumulated Depreciation (2019 - 2023)

Relay Therapeutics (RLAY) has reported Accumulated Depreciation for 5 consecutive years, with $23.6 million the latest figure, recorded in Q4 2023.

• In Q4 2023, Accumulated Depreciation rose 28.24% year-over-year to $23.6 million; the TTM figure through Dec 2023 stood at $23.6 million (up 28.24% YoY), while the FY2023 annual figure was $23.6 million, up 28.24% from the prior year.
• Accumulated Depreciation improved to $23.6 million in Q4 2023 per RLAY's latest filing, from $18.4 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $23.6 million in Q4 2023 and bottomed at $7.0 million in Q4 2019.
• Historically, Accumulated Depreciation has averaged $14.8 million across 5 years, with a median of $14.4 million in 2021.
• Annual changes were most pronounced in 2020 — Accumulated Depreciation jumped 50.84% — and 2022, when it advanced 27.99%.
• Relay Therapeutics' Accumulated Depreciation stood at $7.0 million in 2019, then soared by 50.84% to $10.5 million in 2020, then jumped by 36.44% to $14.4 million in 2021, then rose by 27.99% to $18.4 million in 2022, then advanced by 28.24% to $23.6 million in 2023.
• Business Quant data shows RLAY's Accumulated Depreciation at $23.6 million in Q4 2023, $18.4 million in Q4 2022, and $14.4 million in Q4 2021.